

Bibliography:

- American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019;59:1-18.
- Langer-Gould AM, Anderson WE, Armstrong MJ, et al. The American Academy of Neurology's top five choosing wisely recommendations. *Neurology* 2013. Available at <https://pdfs.semanticscholar.org/6e16/123231bb60600d512fdfff35548f38bd440d.pdf>. Accessed September 7, 2021.
- Ong JJ, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action. *Neurotherapeutics* 2018;15:274-90.
- Silberstein S. D. (2015). Preventive Migraine Treatment. *Continuum (Minneapolis, Minn.)*, 21(4 Headache), 973–989. <https://doi.org/10.1212/CON.000000000000199>
- Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012 Apr 24;78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20. Erratum in: *Neurology*. 2013 Feb 26;80(9):871. PMID: 22529202; PMCID: PMC3335452.
- Ha H, Gonzalez A. Migraine Headache Prophylaxis. *Am Fam Physician*. 2019 Jan 1;99(1):17-24. PMID: 30600979.
- Silberstein SD. Headaches in pregnancy. *J Headache Pain*. 2005;6(4):172–174.
- Dodick DW, Turkel CC, DeGryse RE, Aurora SK,
- Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. *Headache*. 2010 Jun;50(6):921-36. doi: 10.1111/j.1526-4610.2010.01678.x. Epub 2010 May 7. PMID: 20487038.
- Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia*. 2010 Jul;30(7):804-14. doi: 10.1177/0333102410364677. Epub 2010 Mar 17. PMID: 20647171.
- Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenberg AM; BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. *Headache*. 2007 Apr;47(4):486-99. doi: 10.1111/j.1526-4610.2006.00624.x. PMID: 17445098.
- Harvey P, Shah P, Shipley S. An overview of new biologics for migraine prophylaxis. *US Pharm*. 2020;45(1):21-24.
- Peters GL. Migraine overview and summary of current and emerging treatment options. *Am J Manag Care*. 2019;25:-S0. Available at: <https://www.ajmc.com/view/migraine-overview-andsummary-of-current-and-emerging-treatment-options>.
- American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019;59:1-18.

- Clinical Resource, Drugs to prevent migraine in adults. Pharmacist's Letter/Prescriber's Letter. November 2020.
- Clinical Resource, Comparison of triptans and other drugs for acute migraine. Pharmacist's Letter/Prescriber's Letter. March 2020.
- Ha DK, Kim MJ, Han N, et al: Comparative efficacy of oral calcitonin-gene-related peptide antagonists for the treatment of acute migraine: updated meta-analysis. Clin Drug Investig 2021; 41(2):119-132.
- Tolbeyan AS, et al. CGRP monoclonal antibodies along with CGRP receptor antagonists are safe and effective together and compared to standard of care. Abstract P-155. American Headache Society Annual Scientific Meeting. June 3-6, 2021.
<https://doi.org/10.1111/head.14130> Pharmacy Pearls for Prescribers Last Update: 10/28/2021 Approver: Rachelle Davis, Pharm.D
- Mullin K, et al. 2020. Potential for Treatment Benefit of Small Molecule CGRP Receptor Antagonist Plus Monoclonal Antibody in Migraine Therapy. Neurology. 2020; 00: 1-5. doi: 10.1212/WNL.0000000000008944
- Kakete et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study. Headache. 2021; 61:642-652. doi: 10.1111/head.14095